Cannabis and Fibromyalgia Long-Term: Simply Explained
Published: Clinical Rheumatology, March 2026 Researchers: Varadpande, Erridge et al. — Imperial College London / UK Medical Cannabis Registry
1. What Was Studied?
This study used data from the UK Medical Cannabis Registry to look at long-term outcomes for fibromyalgia patients using prescribed medical cannabis — tracking 497 patients across 1, 3, 6, 12, and 18 months of treatment.
Unlike the CANNFIB trial (which tested CBD alone against placebo), this study reflected real-world medical cannabis use — meaning patients used a range of products under clinical supervision, including both CBD and THC-containing formulations. This makes it a useful companion piece: one asks whether CBD works in a controlled trial; this one asks how medical cannabis performs over 18 months in real clinical practice.
2. What Did They Find?
Patients reported improvements across all measured outcomes at every follow-up point — pain, sleep, anxiety, and overall quality of life
Improvements were sustained across 18 months, not just short-term
Participants using higher CBD doses (above 25mg/day) were significantly more likely to report improvement on fibromyalgia-specific scales
Previous cannabis experience was also associated with better outcomes — suggesting familiarity with titration and product selection plays a role
45.67% of patients reported adverse events — most were mild to moderate
The researchers concluded that more randomized controlled trials are needed, but this large real-world dataset provides meaningful evidence to guide future research
3. What This Means
Read alongside the CANNFIB trial, this study tells a more complete story. CBD alone in a controlled trial didn't beat placebo. But medical cannabis — with more flexibility in product, dose, and formulation — showed sustained real-world benefits across 18 months.
The dose finding is particularly useful: CBD above 25mg/day was linked to better outcomes, which suggests the question isn't just whether CBD helps with fibromyalgia, but how much and in what form.
4. What This Does NOT Mean
This is observational data from a registry — not a randomized controlled trial, so causation cannot be confirmed
Adverse events were common — nearly half of patients reported them, though most were mild
Results reflect medically supervised cannabis programs, not over-the-counter products
"Cannabis" here includes THC-containing products under clinical guidance — not equivalent to CBD oil purchased independently
Individual variation was significant — not all patients responded the same way
5. Bottom Line
A real-world study of 497 fibromyalgia patients found sustained improvements across 18 months with medical cannabis — with higher CBD doses linked to better outcomes — offering important context alongside controlled trial data.
🗣️ Mary Jane's Take Two fibromyalgia studies back to back tells the honest story: CBD alone in one trial didn't beat placebo, but medical cannabis in real-world practice showed consistent improvement over 18 months. The difference might be dose, product combination, or individual guidance. That complexity is exactly why education matters.
